This combination therapy induces apoptosis in CRC cells via caspase-3 and PARP activation while also affecting key signaling pathways such as PI3K/Akt, known for regulating cancer cell survival and proliferation [80]. The gene discussed is AKT1; the disease is colorectal carcinoma.